Corvus Pharmaceuticals (CRVS) Accumulated Expenses (2015 - 2026)

Corvus Pharmaceuticals' Accumulated Expenses history runs 12 years deep, the most recent figure standing at $7.0 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 80.44% year-over-year to $7.0 million; the TTM figure through Mar 2026 stood at $7.0 million (up 80.44% YoY), while the FY2025 annual figure was $6.5 million, up 690.98% from the prior year.
• Accumulated Expenses was $7.0 million for Q1 2026 at Corvus Pharmaceuticals, up from $6.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $8.6 million in Q3 2022 to a low of $658000.0 in Q1 2023.
• Historically, Accumulated Expenses has averaged $4.0 million across 5 years, with a median of $4.2 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Accumulated Expenses slumped 91.24% in 2023, then soared 690.98% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $7.5 million in 2022, then tumbled by 90.94% to $684000.0 in 2023, then advanced by 19.88% to $820000.0 in 2024, then jumped by 690.98% to $6.5 million in 2025, then advanced by 7.69% to $7.0 million in 2026.
• The last three Accumulated Expenses figures came in at $7.0 million (Q1 2026), $6.5 million (Q4 2025), and $5.7 million (Q3 2025), per Business Quant data.